azathioprine and Granulomatosis, Wegener's studies

Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.

Research Excerpts

Excerpt	Relevance	Reference
"Current standard therapy for Wegener's granulomatosis and microscopic polyangiitis combines corticosteroids and cyclophosphamide to induce remission, followed by a less toxic immunosuppressant such as azathioprine or methotrexate for maintenance therapy."	9.13	Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. ( Boffa, JJ; Cohen, P; Cordier, JF; Ducroix, JP; Guillevin, L; Hamidou, MA; Khellaf, M; Kyndt, X; Lambert, M; Le Noach, J; Lifermann, F; Mahr, A; Merrien, D; Mouthon, L; Pagnoux, C; Papo, T; Puéchal, X; Ruivard, M; Vinzio, S, 2008)
"The objective of this study was to evaluate the feasibility and safety of high-dose azathioprine pulse (HAP) therapy in the induction of remission in patients with active Wegener's granulomatosis (WG) or progressive lupus nephritis (LN) refractory to or intolerant of cyclophosphamide."	9.11	High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. ( Benenson, E; Fries, JW; Heilig, B; Pollok, M; Rubbert, A, 2005)
"Although cyclophosphamide and prednisolone are effective in treating systemic vasculitis, the optimum treatment regimes and duration of treatment are unknown."	9.08	Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. ( Adu, D; Bacon, PA; Emery, P; Howie, AJ; Luqmani, RA; Michael, J; Pall, A; Richards, NT; Savage, CO, 1997)
"Azathioprine (AZA) is a purine analog that is commonly used for maintaining GPA remission after induction therapy with cyclophosphamide."	5.43	Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. ( Kang, GW; Kim, KC; Lee, IH, 2016)
"Her renal biopsy showed acute tubulointerstitial nephritis and no active glomerulonephritis."	5.33	Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis. ( Bir, K; Carette, S; Herzenberg, AM, 2006)
"Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) could effectively maintain remission of granulomatosis with polyangiitis (Wegener's) (GPA) or microscopic polyangiitis (MPA)."	5.22	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. ( Boffa, JJ; Cohen, P; Delaval, P; Guillevin, L; Hamidou, M; Hanrotel-Saliou, C; Imbert, B; Khouatra, C; Kyndt, X; Lambert, M; Le Jeunne, C; Leské, C; Lifermann, F; Ly, KH; Merrien, D; Mouthon, L; Pagnoux, C; Papo, T; Perrodeau, É; Pertuiset, E; Puéchal, X; Ravaud, P; Roblot, P; Ruivard, M; Smail, A; Subra, JF; Terrier, B; Viallard, JF, 2016)
"Current standard therapy for Wegener's granulomatosis and microscopic polyangiitis combines corticosteroids and cyclophosphamide to induce remission, followed by a less toxic immunosuppressant such as azathioprine or methotrexate for maintenance therapy."	5.13	Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. ( Boffa, JJ; Cohen, P; Cordier, JF; Ducroix, JP; Guillevin, L; Hamidou, MA; Khellaf, M; Kyndt, X; Lambert, M; Le Noach, J; Lifermann, F; Mahr, A; Merrien, D; Mouthon, L; Pagnoux, C; Papo, T; Puéchal, X; Ruivard, M; Vinzio, S, 2008)
"The objective of this study was to evaluate the feasibility and safety of high-dose azathioprine pulse (HAP) therapy in the induction of remission in patients with active Wegener's granulomatosis (WG) or progressive lupus nephritis (LN) refractory to or intolerant of cyclophosphamide."	5.11	High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. ( Benenson, E; Fries, JW; Heilig, B; Pollok, M; Rubbert, A, 2005)
"Although cyclophosphamide and prednisolone are effective in treating systemic vasculitis, the optimum treatment regimes and duration of treatment are unknown."	5.08	Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. ( Adu, D; Bacon, PA; Emery, P; Howie, AJ; Luqmani, RA; Michael, J; Pall, A; Richards, NT; Savage, CO, 1997)
"The patient was treated with corticosteroids and azathioprine throughout pregnancy, and cyclophosphamide was added postpartum."	4.84	Successful term pregnancy in a patient with Wegener's granulomatosis: case report and literature review. ( Hajiioannou, J; Koukoura, O; Linardakis, H; Mantas, N; Sifakis, S, 2008)
"The present study compared the efficacy of mycophenolate mofetil (MMF) with that of azathioprine (AZA) in Korean patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA)."	4.02	The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis. ( Ahn, SS; Lee, LE; Lee, SW; Park, YB; Pyo, JY; Song, JJ, 2021)
"Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health."	3.75	Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. ( Fauci, AS; Haynes, BF; Katz, P; Wolff, SM, 1983)
"The bilateral orbital pseudotumor, polyneuropathy, and serum levels of inflammation reactants (ESR and CRP) improved from therapy with corticosteroids (1 g of methylprednisolone initially) and azathioprine (150 mg/day)."	3.72	Orbital inflammatory pseudotumor due to hypersensitivity vasculitis and mononeuritis multiplex in a patient with atypical, cANCA-positive Wegener's granulomatosis. ( Hein, G; Kaufmann, J; Schulze, E; Stein, G; Strobel, J; Voigt, U, 2003)
"We describe a 67-year-old white man with Wegener's granulomatosis who was treated with cyclophosphamide, then with azathioprine, and who subsequently developed cytomegalovirus retinitis."	3.67	Cytomegalovirus retinitis in rheumatic disease: a case report. ( Finan, MJ; Pressly, T; Roberts, R; Winkler, A, 1987)
"Severe cholestatic jaundice occurred in two patients receiving prednisolone and azathioprine, one for chronic progressive hepatitis, the other for Wegener's granulomatosis."	3.65	[Cholestatic jaundice after azathioprine treatment (author's transl)]. ( Freise, J; May, B; Schmidt, E, 1976)
"A prednisone increase led to remission in 35 patients (80%)."	2.80	Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. ( Brunetta, P; Ding, L; Fervenza, FC; Hoffman, GS; Iklé, D; Kallenberg, CG; Langford, CA; Lim, N; Merkel, PA; Miloslavsky, EM; Monach, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK; Villareal, M, 2015)
"In this open-label trial, etanercept used in combination with standard treatments was well-tolerated in patients with WG."	2.70	Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. ( Bedocs, NM; Crook, S; Hellmann, DB; Hoffman, GS; Stone, JH; Uhlfelder, ML, 2001)
"In addition, Behcet's syndrome appears to be more common than previously assumed and is likely more common than a combination of ANCA-associated vasculitis (AAV) syndromes."	2.45	Necrotizing vasculitis--a 2009 update. ( Sharaf, PH; Yazici, Y, 2009)
"Patients with Wegener's granulomatosis or microscopic polyangiitis or Churg-Strauss syndrome and one or more poor prognostic factors must receive a combination of corticosteroids and immunosuppressants, mainly intravenous pulsed cyclophosphamide."	2.44	[Treatment of ANCA-associated vascularitides]. ( Guillevin, L; Pagnoux, C, 2007)
"MPO-ANCA-associated vasculitis is more frequent in Japan, whereas PR3-ANCA-associated vasculitis is more common in Europe and USA."	2.44	ANCA-associated vasculitis: diagnostic and therapeutic strategy. ( Ozaki, S, 2007)
"Most common and suggestive features of Wegener's granulomatosis are upper (sinusitis, crusting rhinitis, saddle nose deformity, otitis media) and lower (excavated lung nodules, alveolar hemorrhage) respiratory tract, and kidney involvements."	2.44	[Wegener's granulomatosis and microscopic polyangiitis]. ( Pagnoux, C, 2008)
"Until recently, therapies for Wegener granulomatosis and microscopic polyangiitis have been based primarily on a relatively small number of nonrandomized studies."	2.43	Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. ( Goek, ON; Stone, JH, 2005)
"Data on anti-cytokine therapy in Wegener's granulomatosis are controversial, possibly related to differences in study design."	2.43	Advances in the therapy of Wegener's granulomatosis. ( Gross, WL; Hellmich, B; Lamprecht, P, 2006)
"Vasculitis is diagnosed with assurance after intensive evaluation."	2.42	Vasculitis of the nervous system. ( Younger, DS, 2004)
"The two principal aims in the treatment of Wegener's granulomatosis (WG) are to limit the extent and severity of permanent organ damage by controlling the disease promptly and to minimize the short- and long-term morbidity that often results from therapy."	2.41	Treatment of Wegener's granulomatosis. ( Hellmann, DB; Regan, MJ; Stone, JH, 2001)
"These syndromes include Wegener's granulomatosis, allergic angiitis and granulomatosis, and the polyangiitis overlap syndrome."	2.37	Pulmonary vasculitis. ( Fauci, AS; Leavitt, RY, 1986)
"Vasculitis is commoner than supposed, since its manifestations are Protean."	2.37	Acute renal disease in vasculitis. ( Cameron, JS, 1988)
"Midline granuloma (MG), limited Wegener's granulomatosis (LWG), and generalized Wegener's granulomatosis (WG) have been viewed by some investigators as representing an interrelated disease spectrum."	2.35	Midline granuloma and Wegener's granulomatosis: clinical & therapeutic considerations. ( Bole, GG; Schechter, SL; Walker, SE, 1976)
"Azathioprine (AZA) is a purine analog that is commonly used for maintaining GPA remission after induction therapy with cyclophosphamide."	1.43	Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. ( Kang, GW; Kim, KC; Lee, IH, 2016)
"We present a case study of severe hearing impairment in an attempt to raise awareness of ear involvement as an early feature of this unusual condition."	1.43	Toothache and hearing loss: early symptoms of granulomatosis with polyangiitis (GPA). ( Brown, P; Conlon, N; Feighery, C, 2016)
" Complete remission was defined as the absence of disease activity measured by a Birmingham Vasculitis Activity Score for Wegener's granulomatosis of 0 and not qualified by the prednisone dosage at the time."	1.40	Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. ( Azar, L; Hoffman, GS; Langford, CA; Springer, J, 2014)
"Fabry's disease is a rare X-linked, hereditary lysosomal storage disease caused by a deficiency of the enzyme α-galactosidase A."	1.40	A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link. ( Hanaoka, H; Hashiguchi, A; Ishii, T; Konishi, K; Kuwana, M, 2014)
"Optic neuritis in Wegener's granulomatosis without signs of orbital involvement is rare and most likely caused by occlusive vasculitis of the vasa nervorum."	1.39	Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. ( Holbach, L; Huchzermeyer, C; Mardin, C; Rech, J; Schett, G; Zwerina, J, 2013)
"Among 33 cases, 25 were diagnosed as Wegener granulomatosis (WG), seven as microscopic polyangitis (MPA) and one as Churg-Strauss syndrome (SCS)."	1.38	Clinical features and outcomes of ANCA-associated renal vasculitis. ( Brunet, P; Burtey, S; Dussol, B; Seck, SM, 2012)
"We present a patient with Wegener's granulomatosis (WG) who developed SPH soon after the initiation of immunosuppressant therapy."	1.37	Spontaneous perirenal hematoma due to Wegener's granulomatosis after initiation of immunosuppressant. ( Ishii, T; Katada, Y; Saeki, Y, 2011)
"Respiratory obstruction in Wegener granulomatosis can result from subglottic stenosis."	1.35	[Subglottic stenosis in Wegener's granulomatosis]. ( Bakhos, D; Beutter, P; Diot, E; Lescanne, E; Morinière, S, 2008)
"Refractory Wegener's granulomatosis with involvement of the eyes, upper and lower respiratory tracts, and kidneys."	1.35	Maintaining remission in a patient with vasculitis. ( Flossmann, O; Jayne, DR, 2008)
"Glomerulonephritis was present in 22 patients at presentation."	1.34	Clinical features and outcome of pediatric Wegener's granulomatosis. ( Akikusa, JD; Harvey, EA; Hebert, D; Laxer, RM; Schneider, R; Silverman, ED; Thorner, PS, 2007)
"Her renal biopsy showed acute tubulointerstitial nephritis and no active glomerulonephritis."	1.33	Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis. ( Bir, K; Carette, S; Herzenberg, AM, 2006)
"Wegener's granulomatosis is a multisystemic disease characterized by foci of necrotizing vasculitis and granuloma formation."	1.32	Wegener's granulomatosis and subglottic stenosis: management of the airway. ( Alaani, A; Drake Lee, AB; Hogg, RP, 2004)
"Standard therapy of Wegener's granulomatosis is prednisolone in combination with cyclophosphamide."	1.32	[Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis]. ( Stegeman, CA; Tervaert, JW, 2003)
"Since relapses are frequent, these patients should be evaluated frequently."	1.31	Wegener granulomatosis in children and young adults. A case study of ten patients. ( Gothefors, L; Malmer, B; Müller Wiefel, DE; Nilsson, K; Stegmayr, BG; Sundelin, B, 2000)
"We describe a patient with bronchiolitis obliterans organizing pneumonia (BOOP) requiring respiratory support and treated with corticosteroids and cytoxan for presumed Wegener's granulomatosis (WG)."	1.31	Influenza A-associated bronchiolitis obliterans organizing pneumonia mimicking Wegener's granulomatosis. ( Ramos, LG; Staud, R, 2001)
"We report a case of severe Wegener's granulomatosis that caused end-stage renal failure and recurrent flares of sinusitis and pulmonary manifestations."	1.31	Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine. ( Fournier, A; Ghez, D; Henry, I; Lassoued, K; Pruna, A; Westeel, PF, 2002)
"The pattern of relapses is described in a consecutive series of 150 patients with vasculitis."	1.29	Necrotizing vasculitis--relapse despite cytotoxic therapy. ( Adu, D; Bacon, PA; Emery, P; Gordon, M; Greaves, I; Luqmani, RA; Michael, J; Richards, N, 1993)
"We observed systematic vasculitis (polyarteritis nodosa and Wegener's granulomatosis) in several members of 2 different families."	1.29	Familial vasculitis: report of 2 families. ( Cotch, MF; Fauci, AS; Hoffman, GS; Rottem, M, 1994)
"Wegener's granulomatosis is a well-defined systemic vasculitic syndrome that primarily affects the upper and lower respiratory tracts and the kidney."	1.29	Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis. ( Gal, AA; LiVolsi, VA; Masor, JJ, 1994)
"Wegener granulomatosis is more easily recognized as a distinct clinical entity than other vasculitides because the initial clinical features frequently include granulomatous vasculitis of the upper and lower respiratory tract and glomerulonephritis."	1.27	Wegener granulomatosis in pediatric patients. ( Beatty, EC; Duggan, E; Hall, SL; Hellerstein, S; Mauer, SM; Miller, LC, 1985)
"A case of Wegener's granulomatosis is described, in which the presentation was blood stained mucus diarrhoea."	1.27	Severe intestinal involvement in Wegener's granulomatosis. ( Haworth, SJ; Pusey, CD, 1984)
"Eighteen patients with Wegener's granulomatosis with renal involvement have been studied."	1.27	Wegener's granulomatosis: observations on 18 patients with severe renal disease. ( Bowley, N; Evans, DJ; Lockwood, CM; Peters, DK; Pinching, AJ; Pussell, BA; Rees, AJ; Sweny, P, 1983)
"Thirteen patients with Wegener's granulomatosis were seen over 10."	1.27	Wegener's granulomatosis. Clinical features and outcome in 13 patients. ( Brandwein, S; Danoff, D; Esdaile, J; Tannenbaum, H, 1983)
"Course and treatment of a case of Wegener's granulomatosis are reported."	1.27	[Wegener's granulomatosis as a rare cause for kidney failure]. ( Asamer, H; Bolzano, K; Krempler, F; Sandhofer, F, 1983)
"After four years he had a recurrence of his disease while being maintained on azathiorpine."	1.26	Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide. ( Fauci, AS; Jaffe, BF; Monaco, AP; Steinman, TI; Wolff, SM, 1980)
"Treatment with azathioprine and corticosteroids produced transient improvement but three months later a dramatic relapse occurred."	1.26	A rapid unfavorable outcome of Wegener's granulomatosis in early childhood. ( Colombo, A; Duse, M; Fiocca, R; Giannetti, A; Nespoli, L; Perinotto, G; Vitiello, MA, 1979)
"Wegener's granulomatosis is a very rare disease in children; only 10 cases have been reported in the literature."	1.26	Wegener's granulomatosis in childhood. A clinical report based on 3 cases. ( Backman, A; Grahne, B; Holopainen, E; Leisti, J; Paavolainen, M, 1979)
"Two patients with Wegener's granulomatosis, who were in complete remission secondary to cyclophosphamide therapy but who had end-stage renal failure, were treated with renal transplantation."	1.26	Successful renal transplantation in Wegener's granulomatosis. ( Balow, JE; Brown, R; Chazan, J; Fauci, AS; Monoaco, AP; Sahyoun, AI; Steinman, T; Wolff, SM, 1976)
"On the basis of 5 casuistics of Wegener's granulomatosis the author deals with the difficulties of the diagnosis and differential diagnosis, whereby above all is referred to the preculiarities of the cases and the malinterpretation of the diagnoses on admission to the hospital."	1.26	[Contribution to the clinical picture of Wegener's granulomatosis]. ( Ehrig, J; Lehmann, K; Rössner, B; Rübesamen, M; Wessel, G, 1976)
" Haemodialysis was started, cytotoxic drugs were stopped, and steroid dosage was reduced."	1.26	Haemodialysis and transplantation in Wegener's granulomatosis. ( Alexandre, GP; Pirson, Y; van Ypersele de Strihou, C; Vandenbroucke, JM, 1979)
"Three patients with Wegener's granulomatosis are reported."	1.26	Wegener's granulomatosis. Combined therapy with low-dosage systemic corticosteroids, azathioprine and cyclophosphamide in three patients. ( Keczkes, K, 1976)
"A case of Wegener's granulomatosis is presented with control of lung lesions by corticosteriods and renal lesions by azathioprine."	1.25	Wegener's granulomatosis-controlled by azathioprine and corticosteroids. ( Wishart, JM, 1975)
"Bilateral uveitis was the initial manifestation of a limited form of Wegener granulomatosis in a 47-year-old man."	1.25	Limited form of Wegener granulomatosis. Eye involvement as a major sign. ( Coutu, RE; Friedman, E; Klein, M; Lessell, S; Snider, GL, 1975)
"Thirteen patients with Wegener's granulomatosis have been treated with cytotoxic agents."	1.25	Treatment of Wegener's granulomatosis of lung. ( Isreal, HL; Patchfsky, AS, 1975)

Research

Studies (230)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Disease Remission

Timeframe	Studies, this research(%)	All Research%
pre-1990	106 (46.09)	18.7374
1990's	16 (6.96)	18.2507
2000's	48 (20.87)	29.6817
2010's	51 (22.17)	24.3611
2020's	9 (3.91)	2.80

Authors	Studies
Sumichika, Y	3
Yokose, K	3
Sato, S	3
Saito, K	3
Yoshida, S	4
Matsumoto, H	3
Temmoku, J	3
Fujita, Y	3
Matsuoka, N	3
Yashiro-Furuya, M	3
Asano, T	3
Ohkawara, H	3
Watanabe, H	3
Migita, K	3
de Groot, K	2
Aries, PM	2
Haubitz, M	1
Hellmich, B	5
Lamprecht, P	4
Thiel, J	1
Salvador, F	1
Tesar, V	3
Hruskova, Z	1
Garner, S	1
Khalidi, N	1
von Borstel, A	1
Abdulahad, WH	1
Dekkema, G	1
Rutgers, A	1
Stegeman, CA	3
Veldman, J	1
Heeringa, P	1
Sanders, JS	1
Owczarczyk, K	1
Cascino, MD	1
Holweg, C	1
Tew, GW	1
Ortmann, W	1
Behrens, T	1
Schindler, T	1
Langford, CA	8
St Clair, EW	4
Merkel, PA	5
Spiera, R	4
Seo, P	5
Kallenberg, CG	3
Specks, U	5
Lim, N	2
Stone, J	1
Brunetta, P	4
Prunotto, M	1
Busch, MH	1
Aendekerk, JP	1
Oude Lashof, AML	1
van Paassen, P	2
Pyo, JY	1
Lee, LE	1
Ahn, SS	1
Song, JJ	1
Park, YB	1
Lee, SW	1
Ben Ghorbel, I	1
Belfeki, N	1
Baouendi, N	1
Ben Salem, T	1
Houman, MH	1
Hibino, M	1
Kondo, T	1
Puéchal, X	4
Pagnoux, C	8
Guillevin, L	5
Smitienko, I	1
Novikov, P	1
Moiseev, S	1
de Joode, AAE	1
Sanders, JSF	1
Guillevin, LP	1
Hiemstra, TF	2
Flossmann, O	2
Rasmussen, N	3
Westman, K	2
Jayne, DR	6
Kiboshi, T	1
Isoda, K	1
Furukawa, K	1
Wakahara, T	1
Otani, K	1
Ueda, K	1
Konma, J	1
Teramura, K	1
Ueno, N	1
Fujiwara, H	1
Shoda, T	1
Cansu, DÜ	1
Özbülbül, NI	1
Akyol, G	1
Arık, D	1
Korkmaz, C	1
Shim, KY	1
Sohn, SI	1
Kim, YC	1
Daskalakis, GJ	1
Pergialiotis, VP	1
Theodora, MK	1
Antsaklis, PG	1
Sindos, MA	1
Vlahogianopoulos, PG	1
Pappa, KJ	1
Lee, JJY	1
Alsaleem, A	1
Chiang, GPK	1
Limenis, E	1
Sontichai, W	1
Yeung, RSM	1
Akikusa, J	1
Laxer, RM	2
Fortin, PM	2
Tejani, AM	2
Bassett, K	2
Musini, VM	2
Bui, T	1
Chandrakasan, S	1
Poulik, J	1
Fathalla, BM	1
Miloslavsky, EM	3
Hoffman, GS	11
Tchao, NK	3
Viviano, L	1
Ding, L	3
Sejismundo, LP	1
Mieras, K	1
Iklé, D	3
Jepson, B	1
Mueller, M	1
Allen, NB	1
Fervenza, FC	2
Geetha, D	1
Keogh, K	1
Kissin, EY	1
Monach, PA	4
Peikert, T	1
Stegeman, C	1
Ytterberg, SR	2
Stone, JH	6
Cuthbertson, D	1
McAlear, CA	1
Krischer, JP	1
Springer, J	2
Nutter, B	1
Villa-Forte, A	1
Azar, L	2
Yoshikawa, A	1
Takeuchi, T	1
Fujiki, Y	1
Makino, S	1
Hanafusa, T	1
Hanaoka, H	1
Hashiguchi, A	1
Konishi, K	1
Ishii, T	2
Kuwana, M	1
Croft, AP	1
Smith, SW	1
Carr, S	1
Youssouf, S	1
Salama, AD	1
Burns, A	1
Pusey, CD	3
Hamilton, P	1
Brown, N	1
Venning, M	1
Harper, L	2
Morgan, MD	2
Parlow, B	1
Mohiuddin, A	1
Chou, T	1
Cato-Varlack, J	1
Boneparth, A	1
Moorthy, LN	2
Jones, RB	1
Furuta, S	1
Tervaert, JW	2
Hauser, T	2
Luqmani, R	1
Peh, CA	1
Savage, CO	3
Segelmark, M	1
Walsh, M	2
Villareal, M	1
Besada, E	1
Diamantopoulos, AP	1
Brogan, KS	1
Eleftheriou, D	1
Biassoni, L	1
Sebire, N	1
Brogan, PA	1
Perrodeau, É	1
Hamidou, M	1
Boffa, JJ	2
Kyndt, X	2
Lifermann, F	2
Papo, T	2
Merrien, D	2
Smail, A	1
Delaval, P	1
Hanrotel-Saliou, C	1
Imbert, B	1
Khouatra, C	1
Lambert, M	2
Leské, C	1
Ly, KH	1
Pertuiset, E	1
Roblot, P	1
Ruivard, M	2
Subra, JF	1
Viallard, JF	1
Terrier, B	1
Cohen, P	2
Mouthon, L	2
Le Jeunne, C	1
Ravaud, P	1
Sada, KE	1
Yamamura, M	1
Harigai, M	1
Fujii, T	1
Takasaki, Y	1
Amano, K	1
Fujimoto, S	1
Muso, E	1
Murakawa, Y	1
Arimura, Y	1
Makino, H	1
Lee, W	1
Teo, FS	1
Santosa, A	1
Teng, GG	1
Szabó, MZ	1
Pálfi, P	1
Bazsó, A	1
Poór, G	1
Kiss, E	1
Unizony, S	1
Villarreal, M	1
Lu, N	1
Kallenberg, CM	1
Choi, HK	1
Fervenza, F	1
Greco, A	1
Marinelli, C	1
Fusconi, M	1
Macri, GF	1
Gallo, A	1
De Virgilio, A	1
Zambetti, G	1
de Vincentiis, M	1
Ayoub, I	1
Almaani, S	1
Alvarado, A	1
Parikh, SV	1
Rovin, BH	1
Cabral, DA	1
Canter, DL	1
Muscal, E	1
Nanda, K	1
Wahezi, DM	1
Spalding, SJ	1
Twilt, M	1
Benseler, SM	1
Campillo, S	1
Charuvanij, S	1
Dancey, P	1
Eberhard, BA	1
Elder, ME	1
Hersh, A	1
Higgins, GC	1
Huber, AM	1
Khubchandani, R	1
Kim, S	1
Klein-Gitelman, M	1
Kostik, MM	1
Lawson, EF	1
Lee, T	1
Lubieniecka, JM	1
McCurdy, D	1
Morishita, KA	1
Nielsen, SM	1
O'Neil, KM	1
Reiff, A	1
Ristic, G	1
Robinson, AB	1
Sarmiento, A	1
Shenoi, S	1
Toth, MB	1
Van Mater, HA	1
Wagner-Weiner, L	1
Weiss, JE	1
White, AJ	1
Yeung, RS	1
Lee, IH	1
Kang, GW	1
Kim, KC	1
Brown, P	1
Conlon, N	1
Feighery, C	1
Willis, DF	1
Chacko, B	1
Fraser, D	1
Boyle, S	1
Amft, N	1
Singer, O	1
McCune, WJ	2
Mahr, A	2
Hamidou, MA	1
Ducroix, JP	1
Le Noach, J	1
Khellaf, M	1
Vinzio, S	1
Cordier, JF	1
Jourde, N	1
Mancini, J	1
Chiche, L	1
Gelber, AC	1
Watts, R	1
Deger, SM	1
Mutluay, R	1
Ebinc, FA	1
Arinsoy, T	1
Sindel, S	1
Yoshida, M	2
Koch, M	1
Kohnle, M	1
Trapp, R	1
Vanoni, F	1
Bettinelli, A	1
Keller, F	1
Bianchetti, MG	1
Simonetti, GD	1
Cantoni, N	1
Meyer, P	1
Katan, M	1
Kappos, L	1
Hess, C	1
Daikeler, T	1
Sharaf, PH	1
Yazici, Y	1
Huchzermeyer, C	1
Mardin, C	1
Holbach, L	1
Zwerina, J	1
Schett, G	1
Rech, J	1
Katada, Y	1
Saeki, Y	1
Neumann, I	1
Wissing, KM	1
Schmitt, W	1
Lynch, JP	2
Tazelaar, H	1
Kandiah, DA	1
Seck, SM	1
Dussol, B	1
Brunet, P	1
Burtey, S	1
Beji, S	1
Fatma, LB	1
Chebbi, A	1
Rais, L	1
Krid, M	1
Smaoui, W	1
Maiz, HB	1
Zouaghi, K	1
Moussa, FB	1
McMahon, NS	1
Cooper, M	1
Iorember, F	1
English, R	1
Ghez, D	1
Westeel, PF	1
Henry, I	1
Pruna, A	1
Fournier, A	1
Lassoued, K	1
Reinhold-Keller, E	4
Arbach, O	1
Voswinkel, J	1
Lilienthal, T	1
Nölle, B	1
Heller, M	1
Gause, A	1
Gross, WL	6
Hauer, HA	1
Bajema, IM	1
Van Houwelingen, HC	1
Ferrario, F	1
Noël, LH	1
Waldherr, R	1
Bruijn, JA	1
Hagen, EC	1
Kaufmann, J	1
Schulze, E	1
Voigt, U	1
Strobel, J	1
Hein, G	1
Stein, G	1
Sinovich, V	1
Snow, J	1
Hayem, G	1
Roux, F	1
Rouidi, SA	1
Palazzo, E	1
Hénin, D	1
Meyer, O	1
Brunner, A	1
Tzankov, A	1
Akkad, T	1
Lhotta, K	1
Bartsch, G	1
Mikuz, G	1
Kolyvanos Naumann, U	1
Käser, L	1
Vetter, W	1
Ali, SS	1
Rabbani, MA	1
Moinuddin, SS	1
Virani, S	1
Farooque, F	1
Salam, A	1
Ahmad, A	1
Younger, DS	1
Alaani, A	1
Hogg, RP	1
Drake Lee, AB	1
Goek, ON	1
Benenson, E	1
Fries, JW	1
Heilig, B	1
Pollok, M	1
Rubbert, A	1
El Mezni, F	1
Saiji, E	1
Ayadi-Kaddour, A	1
Ismail, O	1
Braham, E	1
Ben Turkia, H	1
Hamzaoui, A	1
Bir, K	1
Herzenberg, AM	1
Carette, S	1
Radhakrishnan, KR	1
Kay, M	1
Wyllie, R	1
Hashkes, PJ	1
Gijzel, A	1
Haagsma, C	1
Veneman, T	1
Ozaki, S	1
Koukoura, O	1
Mantas, N	1
Linardakis, H	1
Hajiioannou, J	1
Sifakis, S	1
Akikusa, JD	1
Schneider, R	1
Harvey, EA	1
Hebert, D	1
Thorner, PS	1
Silverman, ED	1
Bakhos, D	1
Lescanne, E	1
Diot, E	1
Beutter, P	1
Morinière, S	1
Bouroncle, BA	1
Smith, EJ	1
Cuppage, FE	1
Kaeser, HE	1
Fauci, AS	8
Haynes, BF	1
Katz, P	1
Wolff, SM	6
Curtis, JJ	1
Diethelm, AG	1
Herrera, GA	1
Crowell, WT	1
Whelchel, JD	1
Lehmann, H	1
Struve, C	1
Hind, CR	1
Winearls, CG	1
Lockwood, CM	2
Rees, AJ	3
Pepys, MB	1
Haworth, SJ	1
Koyama, T	2
Matsuo, N	1
Watanabe, Y	1
Ojima, M	1
Pinching, AJ	1
Pussell, BA	1
Sweny, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)[NCT00104299]	Phase 2/Phase 3	197 participants (Actual)	Interventional	2005-01-31	Completed
Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis[NCT04871191]	Phase 2	42 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis[NCT00468208]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2008-02-29	Completed
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis[NCT02626845]	Phase 4	3 participants (Actual)	Interventional	2015-12-31	Terminated (stopped due to Slow recruitment)
Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial[NCT00349674]	Phase 3	126 participants	Interventional	1999-01-31	Active, not recruiting
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis[NCT00307645]	Phase 3	160 participants	Interventional	2003-05-31	Terminated
Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis[NCT00001901]	Phase 2	60 participants	Interventional	1999-02-28	Completed
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.[NCT00751517]	Phase 2	0 participants	Interventional		Active, not recruiting
Wegener's Granulomatosis Etanercept Trial (WGET)[NCT00005007]	Phase 2/Phase 3	181 participants	Interventional	2000-06-30	Completed
Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials[NCT00357903]	Phase 3	639 participants (Actual)	Interventional	1997-04-30	Completed
Steroid Treatment as Anti-inflammatory and Neuroprotective Agent Following Out-of-Hospital Cardiac Arrest. A Randomized Trial[NCT04624776]	Phase 2	158 participants (Actual)	Interventional	2020-10-10	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) score of 0 with prednisone taper successfully completed at six months. The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease. (NCT00104299)
Timeframe: 6 months post-randomization

Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization

Intervention	Participants (Number)
Rituximab	63
Control Group	52

"The 2-sided 95% CI of the percentage of participants who have a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and have successfully completed the glucocorticoid taper by 6 months post-randomization and the 2-sided 95% CI of the difference between two arms for assessing the superiority of rituximab to control~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 6 months post-randomization

Number of Subjects Experiencing Serious Adverse Events

Intervention	participants (Number)
Rituximab	62
Control Group	51

Number of subjects according to originally received treatment that experienced a serious adverse event through 18 months post-randomization or prior to being censored from analyses due to crossover, switching to open-label treatment, or best medical judgment for censor. Events are categorized by coded system organ classes (SOC). Within each SOC, a participant was counted once if the participant reported one or more events coded to that SOC. (NCT00104299)
Timeframe: Randomization to censor at Crossover, Open-label or Best Medical Judgment (up to 18 months post-randomization)

Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy

Intervention	participants (Number)
	# Participants with at least one SAE	Blood and Lymphatic System Disorders	Cardiac Disorders	Eye Disorders	Gastrointestinal Disorders	General Disorders and Administration Site	Immune System Disorders	Infections and Infestations	Injury, Poisoning, and Procedural Complications	Investigations	Metabolism and Nutrition Disorders	Musculoskeletal and Connective Tissue Disorders	Neoplasms Benign, Malignant, and Unspecified	Nervous System Disorders	Pregnancy, Puerperium, and Perinatal Conditions	Psychiatric Disorders	Renal and Urinary Disorders	Respiratory, Thoracic, and Mediastinal Disorders	Vascular Disorders
Control Group	37	5	2	1	1	3	2	12	0	0	2	3	2	0	0	1	3	8	7
Rituximab	42	4	2	1	4	5	2	12	2	2	2	2	1	1	1	1	4	8	1

The adverse event rate for the following events considered related to vasculitis: Death; Grade 2 or higher leukopenia or thrombocytopenia; Grade 3 or higher infections; Hemorrhagic cystitis (grade 2 or lower needs confirmation by cytoscopy); Malignancy; Venous thromboembolic event (deep venous thrombosis or pulmonary embolism); Hospitalization resulting either from the disease or from a complication due to study treatment; Infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions (including cytokine release allergic reaction); Cerebrovascular accident (NCT00104299)
Timeframe: Through common close-out (defined as 18 months after the last participant is enrolled in the trial)

The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups

Intervention	participants (Number)
	Death	Grade 2 or Higher Leukopenia	Grade 2 or Higher Thrombocytopenia	Grade 3 or Higher Infections	Hemorrhagic Cystitis (Grade 2 or Lower)	Malignancy	Venous Thromboembolic Event	Hospitalization Resulting from the Disease	Cerebrovascular Accident (CVA)	Infusion Reactions Leading to Infusion Disc.
Control Group	2	23	1	16	1	2	8	7	1	0
Rituximab	2	7	4	18	2	5	6	16	1	1

"Duration of complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of Prednisone to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization

The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups

Intervention	Days (Number)
	25% Quartile (95%CI)	50% Quartile (95%CI)	75% Quartile (95%CI)
Control Group	230	NA	NA
Rituximab	243	NA	NA

Duration of remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of glucocorticoid by 6 months post-randomization to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing. (NCT00104299)
Timeframe: 18 months post-randomization

Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups

Intervention	Days (Number)
	25% Quartile (95%CI)	50% Quartile (95%CI)	75% Quartile (95%CI)
Control Group	168	NA	NA
Rituximab	246	NA	NA

"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and completing taper of glucocorticoid by 6 months post-randomization.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization

Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups

Intervention	Days (Number)
	25% Quartile (95%CI)	50% Quartile (95%CI)	75% Quartile (95%CI)
Control Group	177	183	266
Rituximab	176	180	189

"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization

Disease Improvement

Intervention	Days (Number)
	25% Quartile (95%CI)	50% Quartile (95%CI)	75% Quartile (95%CI)
Control Group	29	43	112
Rituximab	30	57	119

"Disease improvement was measured by a reduction in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG).~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination, up to 3 years and 4 months.

Disease Relapse

Intervention	participants (Number)
Open-label Abatacept	18

"Disease relapse was measured by a rise in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of greater than or equal to 1 after achieving remission.~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination, up to 3 years and 4 months.

Disease Remission

Intervention	participants (Number)
Open-label Abatacept	3

"Disease remission was measured by a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0.~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination,up to 3 years and 4 months.

Meeting Common Closing

Intervention	participants (Number)
Open-label Abatacept	16

The number of subjects that reached the common closing date. (NCT00468208)
Timeframe: Number assessed at the time of common closing, up to 3 years and 4 months.

Safety of Abatacept - Number of Participants With Adverse Events

Intervention	participants (Number)
Open-label Abatacept	14

"This study examined the safety profile of this agent when used in Wegener's granulomatosis. Information was gathered on all adverse events with specific events being identified in the protocol for analysis that included the following:~Infection~Infusion reactions~Cytopenias~Transaminase elevation~Skin reactions~GI side effects~Malignancy~All adverse events were reportable for this study." (NCT00468208)
Timeframe: Measured continuously from the screening visit through to the 6 month post-treatment study visit, up to 3 years and 4 months.

ACR20 at Month 3 in Adults

Intervention	participants (Number)
	Serious adverse events	Non-serious adverse events	Infection	Infusion related (systemic)	Infusion related( intravenous site reaction)	Cytopenia
Open-label Abatacept	7	16	14	1	1	4

American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults (NCT00357903)
Timeframe: Baseline and month 3

C-Reactive Protein

Childhood Health Assessment Questionnaire

Intervention	Participants (Number)
Adult Participants	372

Intervention	mg/dL (Mean)
Adult Participants	1.37
Pediatric Participants	2.11

Childhood Health Assessment Questionnaire (CHAQ) disability index, having a range of 0 (no difficulty) to 3 (unable to do). (NCT00357903)
Timeframe: Month 12

Death

Intervention	Units on a scale (Mean)
Pediatric Participants	1.08

Occurrence of death on study within 30 days of the last dose of etanercept (NCT00357903)
Timeframe: Up to 10 years

Dosing Period

Health Assessment Questionnaire Disability Index

Intervention	Participants (Number)
Adult Participants	23
Pediatric Participants	0

Intervention	Days (Mean)
Adult Participants	2535.4
Pediatric Participants	2153.6

Health Assessment Questionnaire Disability Index (HAQ DI). This index is a weighted average of 24 items, each scored 0 (no difficulty) to 3 (unable to function). (NCT00357903)
Timeframe: Month 12

JRA DOI 30 at Month 3 in Juveniles

Intervention	Units on a scale (Mean)
Adult Participants	0.96

Juvenile Rheumatoid Arthritis Definition of Improvement 30 (JRA DOI 30), defined as a 30% improvement from baseline in 3 of 6 items (including Childhood Health Assessment Questionnaire, disease severity, overall well-being, and erythrocyte sedimentation rate) and a worsening of >30% in at most one of the remaining items. (NCT00357903)
Timeframe: Baseline and month 3

Lymphoma

Intervention	Participants (Number)
Pediatric Participants	46

Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept (NCT00357903)
Timeframe: Up to 10 years

Malignancy

Intervention	Participants (Number)
Adult Participants	6
Pediatric Participants	0

Occurrence of one or more malignancies on study within 30 days of the last dose of etanercept (NCT00357903)
Timeframe: Up to 10 years

Serious Infectious Event

Intervention	Participants (Number)
Adult Participants	48
Pediatric Participants	0

Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication. A serious infectious event is a serious adverse event that is infectious. (NCT00357903)
Timeframe: Up to 10 years

Standardized Incidence Rate for All SEER Cancers

Intervention	Participants (Number)
Adult Participants	114
Pediatric Participants	8

Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system. (NCT00357903)
Timeframe: up to 10 years

Swollen Joint Count

Tender Joint Count

Intervention	Observed count / expected count (Number)
Adult Participants	1.30
Pediatric Participants	0.00

Intervention	Joints (Mean)
Adult Participants	9.14
Pediatric Participants	11.93

Number of tender joints, as assessed by the investigator using criteria based on pressure and joint manipulation (NCT00357903)
Timeframe: Month 12

Total Exposure Adjusted Rate of Deaths

Intervention	Joints (Mean)
Adult Participants	9.55
Pediatric Participants	11.60

Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept (NCT00357903)
Timeframe: Up to 10 years

Total Exposure Adjusted Rate of Lymphomas

Intervention	Deaths per 100 participant-years (Number)
Adult Participants	0.57
Pediatric Participants	0.00

Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept (NCT00357903)
Timeframe: Up to 10 years

Total Exposure Adjusted Rate of Malignancies

Intervention	Lymphomas per 100 participant-years (Number)
Adult Participants	0.15
Pediatric Participants	0.00

Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept (NCT00357903)
Timeframe: Up to 10 years

Total Exposure Adjusted Rate of Serious Adverse Events

Intervention	Malignancies per 100 participant-years (Number)
Adult Participants	1.41
Pediatric Participants	0.00

Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure * 100) (NCT00357903)
Timeframe: Up to 10 years

Total Exposure Adjusted Rate of Serious Infectious Events

Intervention	Events per 100 participant-years (Number)
Adult Participants	20.95
Pediatric Participants	12.87

Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept (NCT00357903)
Timeframe: Up to 10 years

Total Exposure to Etanercept With Gaps

Intervention	Events per 100 participant-years (Number)
Adult Participants	5.18
Pediatric Participants	3.22

Total participant exposure to etanercept (Enbrel) with gaps (NCT00357903)
Timeframe: Up to 10 years

Article	Year
[Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:1 Topics: Azathioprine; Germany; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Microscop	2020
ANCA associated vasculitis. European journal of internal medicine, 2020, Volume: 74 Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic;	2020
Updates in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis: At a crossroad. Presse medicale (Paris, France : 1983), 2020, Volume: 49, Issue:3 Topics: Adrenal Cortex Hormones; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; C	2020
[Granulomatosis with Polyangiitis Complicated with Gastrointestinal Perforation: A Case Report and Review of Literature]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2017, Volume: 40, Issue:5 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biomarkers; Cyclophosphamide; Early Diagnosis;	2017
Do pulmonary findings of granulomatosis with polyangiitis respond to anti-tuberculosis treatment? Rheumatology international, 2018, Volume: 38, Issue:6 Topics: Adult; Antibodies, Antineutrophil Cytoplasmic; Antitubercular Agents; Azathioprine; Female; Granulom	2018
[ANCA-associated vasculitides : State of the art]. Zeitschrift fur Rheumatologie, 2019, Volume: 78, Issue:6 Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic;	2019
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. Pediatric rheumatology online journal, 2019, Jun-26, Volume: 17, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathio	2019
Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. The Cochrane database of systematic reviews, 2013, Jan-31, Issue:1 Topics: Adult; Azathioprine; Chemotherapy, Adjuvant; Drug Therapy, Combination; Glucocorticoids; Granulomato	2013
[Recent advances in the treatment of antineutrophil cytoplasm antibody associated vasculitides]. Orvosi hetilap, 2015, Oct-11, Volume: 156, Issue:41 Topics: Algorithms; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; Clinical Trial	2015
Clinic manifestations in granulomatosis with polyangiitis. International journal of immunopathology and pharmacology, 2016, Volume: 29, Issue:2 Topics: Azathioprine; Cyclophosphamide; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Incidence	2016
Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. Current opinion in rheumatology, 2017, Volume: 29, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Azathioprine; Granulomatosis with Polyangiitis; Humans; Immu	2017
[Wegener's granulomatosis and microscopic polyangiitis]. La Revue du praticien, 2008, Mar-15, Volume: 58, Issue:5 Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathiopr	2008
[Treatment of systemic vasculitides]. La Revue du praticien, 2008, Mar-15, Volume: 58, Issue:5 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Azathioprine; Ch	2008
[Strategy of immunosuppressants usage for subjects with loss of renal function and infection control on RPGN]. Nihon Jinzo Gakkai shi, 2009, Volume: 51, Issue:2 Topics: Autoantibodies; Azathioprine; Churg-Strauss Syndrome; Contraindications; Cyclophosphamide; Cyclospor	2009
Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Adult; Azathioprine; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunoglobulins, Int	2009
Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:2 Topics: Adolescent; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil C	2010
Necrotizing vasculitis--a 2009 update. Bulletin of the NYU hospital for joint diseases, 2009, Volume: 67, Issue:3 Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; Behcet Syndrome; Churg-Str	2009
Protracted superficial Wegener's granulomatosis. The Australasian journal of dermatology, 2003, Volume: 44, Issue:3 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; Drug	2003
[Wegener's granulomatosis (morbus Wegener)]. Praxis, 2003, Nov-12, Volume: 92, Issue:46 Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Diagnosis, D	2003
Vasculitis of the nervous system. Current opinion in neurology, 2004, Volume: 17, Issue:3 Topics: Azathioprine; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Giant Cell Arte	2004
[New aspects in ANCA-associated vasculitides]. Medizinische Klinik (Munich, Germany : 1983), 2004, Sep-15, Volume: 99, Issue:9 Topics: Animals; Antibodies, Antineutrophil Cytoplasmic; Autoantigens; Azathioprine; CD28 Antigens; Churg-St	2004
Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Current opinion in rheumatology, 2005, Volume: 17, Issue:3 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Etanercept; Granulomatosis w	2005
Advances in the therapy of Wegener's granulomatosis. Current opinion in rheumatology, 2006, Volume: 18, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Etan	2006
[Treatment of ANCA-associated vascularitides]. Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:5 Pt 2 Topics: Adrenal Cortex Hormones; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodies,	2007
ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergology international : official journal of the Japanese Society of Allergology, 2007, Volume: 56, Issue:2 Topics: Adrenal Cortex Hormones; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biological Products;	2007
Successful term pregnancy in a patient with Wegener's granulomatosis: case report and literature review. Fertility and sterility, 2008, Volume: 89, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Female; Granulomatosis with	2008
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Annals of internal medicine, 1983, Volume: 98, Issue:1 Topics: Adolescent; Adult; Aged; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Administrati	1983
Azathioprine. International journal of dermatology, 1981, Volume: 20, Issue:7 Topics: Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Colitis, Ulcerative; Crohn Diseas	1981
[Systemic diseases--the significance of early diagnosis exemplified by systemic lupus erythematosus and Wegener's granulomatosis]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1993, Volume: 48, Issue:12 Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; L	1993
Update on immunosuppressive therapy. Current opinion in rheumatology, 1998, Volume: 10, Issue:3 Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cycl	1998
Management of systemic vasculitis. Best practice & research. Clinical rheumatology, 2001, Volume: 15, Issue:2 Topics: Azathioprine; Cyclophosphamide; Drug Combinations; Glucocorticoids; Granulomatosis with Polyangiitis	2001
Primary systemic vasculitis. Minerva medica, 2001, Volume: 92, Issue:5 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Churg-Strauss	2001
Treatment of Wegener's granulomatosis. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:4 Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; I	2001
Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. Cleveland Clinic journal of medicine, 2002, Volume: 69 Suppl 2 Topics: Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents;	2002
Immunosuppressive therapy in rheumatic disease. The Medical clinics of North America, 1977, Volume: 61, Issue:2 Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr	1977
Problems with immunosuppressive agents in renal disease. Journal of clinical pathology. Supplement (Royal College of Pathologists), 1975, Volume: 9 Topics: Animals; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppressive	1975
Midline granuloma and Wegener's granulomatosis: clinical & therapeutic considerations. The Journal of rheumatology, 1976, Volume: 3, Issue:3 Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Drug Therapy,	1976
[The diagnosis and treatment of Wegener's granulomatosis]. Duodecim; laaketieteellinen aikakauskirja, 1991, Volume: 107, Issue:11 Topics: Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Azathioprine; Biopsy; Cyclophosphamide; Glom	1991
Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation, 1990, Volume: 50, Issue:6 Topics: Adult; Azathioprine; Cyclophosphamide; Cyclosporins; Granulomatosis with Polyangiitis; Humans; Kidne	1990
Development of multiple carcinomas in a long term survivor of Wegener's granulomatosis treated with immunosuppressive drugs. New York state journal of medicine, 1989, Volume: 89, Issue:12 Topics: Adult; Azathioprine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Gran	1989
Cytotoxic drugs: their clinical application to the rheumatic diseases. Seminars in arthritis and rheumatism, 1986, Volume: 15, Issue:4 Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica	1986
Pulmonary vasculitis. The American review of respiratory disease, 1986, Volume: 134, Issue:1 Topics: Adrenal Cortex Hormones; Azathioprine; Behcet Syndrome; Chlorambucil; Connective Tissue Diseases; Cy	1986
Acute renal disease in vasculitis. Annales de medecine interne, 1988, Volume: 139, Issue:2 Topics: Actuarial Analysis; Acute Disease; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis;	1988
Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders. The Medical clinics of North America, 1985, Volume: 69, Issue:4 Topics: Arthritis, Reactive; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophos	1985
[Wegener's granulomatosis]. Ryumachi. [Rheumatism], 1985, Volume: 25, Issue:4 Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Eye; Granulomatosis with Polyangiitis; Hu	1985
[Goodpasture's syndrome]. Polskie Archiwum Medycyny Wewnetrznej, 1973, Volume: 50, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Glomerular Basement Membrane Disease; Antibodies; Azathioprine; Baseme	1973
[Auto-immune diseases and immunodepressive therapy. II. Current clinical indications]. Acta clinica Belgica, 1974, Volume: 29, Issue:6 Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Arteritis; Autoimmune	1974
Cytotoxic drugs in treatment of nonmalignant diseases. Annals of internal medicine, 1972, Volume: 76, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlor	1972
Immunosuppressive therapy. 2. The New England journal of medicine, 1972, Aug-10, Volume: 287, Issue:6 Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin	1972
Immunosuppressant agents in the treatment of glomerulonephritis. 2. Cytotoxic drugs. Journal of the Royal College of Physicians of London, 1971, Volume: 5, Issue:4 Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antilymphocyte Serum; Antineoplastic Agents; Azath	1971
[Wegener's granulomatosis: Pathogenesis, pathophysiology, and therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 2 Topics: Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Drug Therapy, Combination; Granulomatosis	2006

Article	Year
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI insight, 2020, 09-17, Volume: 5, Issue:18 Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Biomarkers; Case-Contr	2020
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism, 2013, Volume: 65, Issue:9 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cross-Over Studies; Cyclophosphamide; D	2013
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6 Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Der	2015
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:6 Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived;	2015
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:3 Topics: Azathioprine; Disease-Free Survival; Follow-Up Studies; Granulomatosis with Polyangiitis; Humans; Ki	2016
Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis research & therapy, 2015, Nov-02, Volume: 17 Topics: Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combin	2015
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:6 Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil	2016
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. The New England journal of medicine, 2008, Dec-25, Volume: 359, Issue:26 Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, C	2008
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA, 2010, Dec-01, Volume: 304, Issue:21 Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Glomerular Filtration Rat	2010
Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney international, 2002, Volume: 62, Issue:5 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; Cyclophosphamide; Glomerular Filtratio	2002
High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clinical rheumatology, 2005, Volume: 24, Issue:3 Topics: Adult; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; Cyclophosphamide; Dose-Response	2005
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Annals of internal medicine, 1983, Volume: 98, Issue:1 Topics: Adolescent; Adult; Aged; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Administrati	1983
Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM : monthly journal of the Association of Physicians, 1997, Volume: 90, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cyclophosphamide; Dr	1997
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis and rheumatism, 2001, Volume: 44, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combi	2001
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis and rheumatism, 2001, Volume: 44, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combi	2001
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis and rheumatism, 2001, Volume: 44, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combi	2001
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis and rheumatism, 2001, Volume: 44, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combi	2001
Immunosuppressive therapy in rheumatic disease. The Medical clinics of North America, 1977, Volume: 61, Issue:2 Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr	1977
Immunosuppressive therapy. 2. The New England journal of medicine, 1972, Aug-10, Volume: 287, Issue:6 Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin	1972

Article	Year
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-20, Volume: 259, Issue:2 Topics: Aged; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Leuk	2023
Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment? Clinical journal of the American Society of Nephrology : CJASN, 2020, 10-07, Volume: 15, Issue:10 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangi	2020
Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PloS one, 2020, Volume: 15, Issue:7 Topics: Adult; Aged; Azathioprine; B-Lymphocyte Subsets; B-Lymphocytes; Cell Proliferation; Cytokines; Femal	2020
Spondylitis as a Rare Manifestation of Granulomatosis With Polyangiitis. Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:2 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Diagnosis, Differential; Epi	2021
The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Yonsei medical journal, 2021, Volume: 62, Issue:6 Topics: Azathioprine; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Microscopic Polyan	2021
Granulomatosis with polyangiitis in Tunisia. Reumatismo, 2017, May-22, Volume: 69, Issue:1 Topics: Adult; Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biomarkers; Cycl	2017
Dacryoadenitis with Ptosis and Diplopia as the Initial Presentation of Granulomatosis with Polyangiitis. Internal medicine (Tokyo, Japan), 2017, Oct-01, Volume: 56, Issue:19 Topics: Adrenal Cortex Hormones; Aged; Asian People; Azathioprine; Dacryocystitis; Diplopia; Female; Granulo	2017
Reply. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:1 Topics: Azathioprine; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Microscopic Polyangiitis; P	2018
Does the revised definition of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) indicate the need for a new treatment? Comment on the article by Puéchal et al. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:1 Topics: Azathioprine; Churg-Strauss Syndrome; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Mic	2018
Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology (Oxford, England), 2017, 11-01, Volume: 56, Issue:11 Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil	2017
Central Retinal Arterial Occlusion in Granulomatosis with Polyangiitis. Korean journal of ophthalmology : KJO, 2018, Volume: 32, Issue:6 Topics: Azathioprine; Coloring Agents; Drug Combinations; Female; Fluorescein Angiography; Glucocorticoids;	2018
Pregnancy in a patient with eosinophilic granulomatosis with polyangiitis. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2019, Volume: 39, Issue:4 Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Granulomatosis with Polyangiitis; Humans; Im	2019
Granulomatosis with polyangiitis presenting as Henoch-Schönlein purpura in children. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013, Volume: 19, Issue:4 Topics: Abdominal Pain; Anti-Infective Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Child;	2013
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the rheumatic diseases, 2014, Volume: 73, Issue:7 Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The	2014
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the rheumatic diseases, 2014, Volume: 73, Issue:7 Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The	2014
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the rheumatic diseases, 2014, Volume: 73, Issue:7 Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The	2014
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the rheumatic diseases, 2014, Volume: 73, Issue:7 Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The	2014
Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine, 2014, Volume: 93, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Drug Administration Schedule; Femal	2014
Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Drug Therapy, Combination; Female	2014
Gastrointestinal involvement at the onset of granulomatosis with polyangiitis: A case report. Modern rheumatology, 2017, Volume: 27, Issue:1 Topics: Adult; Azathioprine; Biopsy; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppre	2017
A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link. BMC nephrology, 2014, Oct-01, Volume: 15 Topics: Adult; alpha-Galactosidase; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies,	2014
Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. Kidney international, 2015, Volume: 87, Issue:4 Topics: Abortion, Spontaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathio	2015
Abdominal pain, rash, and arthritis. Clinical pediatrics, 2015, Volume: 54, Issue:5 Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis; Azathioprine;	2015
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis]. Zeitschrift fur Rheumatologie, 2015, Volume: 74, Issue:2 Topics: Antirheumatic Agents; Azathioprine; Drug Administration Schedule; Drug Therapy, Combination; Granulo	2015
Reply: To PMID 24943239. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:7 Topics: Antibodies, Monoclonal, Murine-Derived; Azathioprine; Female; Granulomatosis with Polyangiitis; Huma	2015
Does Concomitant Methotrexate During Rituximab Treatment in Granulomatosis With Polyangiitis (Wegener's) Increase the Risk of Severe Infection? Comment on the Article by Azar et al. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:7 Topics: Antibodies, Monoclonal, Murine-Derived; Azathioprine; Female; Granulomatosis with Polyangiitis; Huma	2015
Multifocal noninfectious osteitis as a presentation of pediatric granulomatosis with polyangiitis (Wegener's). Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:10 Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azathioprine; Child; Dose-Response Relationship, Drug	2015
Eosinophilic Granulomatosis with Polyangiitis preceding allergic bronchopulmonary aspergillosis. European annals of allergy and clinical immunology, 2015, Volume: 47, Issue:6 Topics: Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Azathioprine; Bi	2015
Quiz Page February 2016: Acute Kidney Injury in a Patient With Granulomatosis With Polyangiitis Receiving Maintenance Immunosuppressive Therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:2 Topics: Acute Kidney Injury; Azathioprine; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agent	2016
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:10 Topics: Adolescent; Adrenal Cortex Hormones; Age Distribution; Antibodies, Antineutrophil Cytoplasmic; Asia;	2016
Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. Rheumatology international, 2016, Volume: 36, Issue:7 Topics: Adult; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Bronchoscopy; Drug Hypersensitivity; Gr	2016
Toothache and hearing loss: early symptoms of granulomatosis with polyangiitis (GPA). BMJ case reports, 2016, Jul-19, Volume: 2016 Topics: Adult; Azathioprine; Cyclophosphamide; Diagnosis, Differential; Diphosphonates; Female; Granulomatos	2016
Rash and fever in a man with granulomatosis with polyangiitis (Wegener's). Nephrology (Carlton, Vic.), 2016, Volume: 21, Issue:9 Topics: Azathioprine; Biopsy; Drug Eruptions; Exanthema; Fever; Glucocorticoids; Granulomatosis with Polyang	2016
Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis. The Journal of rheumatology, 2016, Volume: 43, Issue:12 Topics: Antibodies, Monoclonal, Murine-Derived; Anus Diseases; Azathioprine; Biopsy, Needle; Crohn Disease;	2016
Maintaining remission in a patient with vasculitis. Nature clinical practice. Rheumatology, 2008, Volume: 4, Issue:9 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamid	2008
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. The New England journal of medicine, 2009, Mar-26, Volume: 360, Issue:13 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Female; Glomerular Filtration Rate; Granulomat	2009
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. The New England journal of medicine, 2009, Mar-26, Volume: 360, Issue:13 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Granulomatosis with Polyangiitis; Humans; Immu	2009
Vasculitis syndromes: vasculitis therapy--between Scylla and Charybdis. Nature reviews. Rheumatology, 2009, Volume: 5, Issue:4 Topics: Antirheumatic Agents; Azathioprine; Granulomatosis with Polyangiitis; Humans; Methotrexate	2009
Renal cell carcinoma associated immunosuppressive therapy: a case report with Wegener's granulomatosis. Rheumatology international, 2009, Volume: 30, Issue:1 Topics: Azathioprine; Carcinoma, Renal Cell; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, C	2009
A case report of successful long-term relapse control by protein-a immunoadsorption in an immunosuppressive-treated patient with end-stage renal disease due to Wegener's granulomatosis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13, Issue:2 Topics: Adult; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Humans; Immunosorbe	2009
A confusing patient's history: small or large vessel vasculitis? Rheumatology international, 2010, Volume: 30, Issue:12 Topics: Autoantibodies; Azathioprine; Conjunctivitis; Cyclophosphamide; Diagnosis, Differential; Drug Therap	2010
Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. Clinical rheumatology, 2013, Volume: 32 Suppl 1 Topics: Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Dose-Response Relationship,	2013
Spontaneous perirenal hematoma due to Wegener's granulomatosis after initiation of immunosuppressant. Modern rheumatology, 2011, Volume: 21, Issue:2 Topics: Azathioprine; Female; Granulomatosis with Polyangiitis; Hematoma; Humans; Immunosuppressive Agents;	2011
Therapeutic interventions for systemic vasculitis. JAMA, 2010, Dec-01, Volume: 304, Issue:21 Topics: Antirheumatic Agents; Azathioprine; Clinical Trials as Topic; Granulomatosis with Polyangiitis; Huma	2010
Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. Seminars in respiratory and critical care medicine, 2011, Volume: 32, Issue:3 Topics: Adrenal Cortex Hormones; Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cy	2011
Development of granulomatosis with polyangiitis (Wegener): listen to the patient. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:5 Topics: Adult; Azathioprine; Breast Diseases; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Hu	2011
Clinical features and outcomes of ANCA-associated renal vasculitis. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2012, Volume: 23, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated V	2012
A case of exorbitism in association with Wegener's granulomatosis with renal involvement. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2012, Volume: 23, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Azathioprine; Cyclo	2012
Just chronic sinusitis? Clinical pediatrics, 2012, Volume: 51, Issue:11 Topics: Adolescent; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biomarkers; Biopsy; Chronic Diseas	2012
Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:2 Topics: Adult; Anti-Infective Agents, Urinary; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplas	2002
[How long should cyclophosphamide therapy of Wegener's granulomatosis continue?]. Deutsche medizinische Wochenschrift (1946), 2002, Sep-13, Volume: 127, Issue:37 Topics: Adjuvants, Immunologic; Administration, Oral; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-	2002
[Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients]. Deutsche medizinische Wochenschrift (1946), 2002, Sep-13, Volume: 127, Issue:37 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Cyclophosphamide; Cystitis; Female; F	2002
Orbital inflammatory pseudotumor due to hypersensitivity vasculitis and mononeuritis multiplex in a patient with atypical, cANCA-positive Wegener's granulomatosis. Rheumatology international, 2003, Volume: 23, Issue:3 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biomarkers; Drug Therapy, Combination; Electro	2003
JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint bone spine, 2003, Volume: 70, Issue:5 Topics: Aged; Azathioprine; Fatal Outcome; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans	2003
Wegener's granulomatosis presenting with gross hematuria due to prostatitis. Virchows Archiv : an international journal of pathology, 2004, Volume: 444, Issue:1 Topics: Azathioprine; Biopsy; Granulomatosis with Polyangiitis; Hematuria; Humans; Immunosuppressive Agents;	2004
[Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis]. Nederlands tijdschrift voor geneeskunde, 2003, Nov-15, Volume: 147, Issue:46 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; G	2003
Maximum tolerable dose of cyclophosphamide and azathioprine in Pakistani patients with primary renal disease. JPMA. The Journal of the Pakistan Medical Association, 2004, Volume: 54, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Chi-Square Distribution; Child; Cyclophosp	2004
High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology (Oxford, England), 2004, Volume: 43, Issue:10 Topics: Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Mal	2004
Wegener's granulomatosis and subglottic stenosis: management of the airway. The Journal of laryngology and otology, 2004, Volume: 118, Issue:10 Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Combined Modality Therapy; Cyclophosphamide; Dr	2004
[Wegener granulomatosis: a pulmonary pediatric form]. Annales de pathologie, 2005, Volume: 25, Issue:3 Topics: Abscess; Adrenal Cortex Hormones; Azathioprine; Child; Cyclophosphamide; Female; Granulomatosis with	2005
Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Acute Disease; Azathioprine; Diagnosis, Differential; Drug Hypersensitivity; Female; Granulomatosis	2006
Wegener granulomatosis mimicking inflammatory bowel disease in a pediatric patient. Journal of pediatric gastroenterology and nutrition, 2006, Volume: 43, Issue:3 Topics: Abdominal Pain; Adolescent; Antibodies, Antineutrophil Cytoplasmic; Appendectomy; Azathioprine; Biop	2006
A therapy resistant vasculitis? The Netherlands journal of medicine, 2006, Volume: 64, Issue:9 Topics: Azathioprine; Diagnosis, Differential; Epstein-Barr Virus Infections; Fatal Outcome; Female; Granulo	2006
Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis and rheumatism, 2007, Jun-15, Volume: 57, Issue:5 Topics: Adolescent; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Child; Cyclophosphamide; Drug Ther	2007
[Subglottic stenosis in Wegener's granulomatosis]. Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 2008, Volume: 125, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Imm	2008
Treatment of Wegener's granulomatosis with Imuran. The American journal of medicine, 1967, Volume: 42, Issue:2 Topics: Aged; Azathioprine; Granulomatosis with Polyangiitis; Humans; Male	1967
Cytostatic drugs in the treatment of severe vasculitides. Indications, results and risks. European neurology, 1984, Volume: 23, Issue:6 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combin	1984
Recurrence of Wegener's granulomatosis in a cadaver renal allograft. Transplantation, 1983, Volume: 36, Issue:4 Topics: Azathioprine; Cyclophosphamide; Glomerulonephritis; Granulomatosis with Polyangiitis; Humans; Kidney	1983
[Liver changes in Wegener's granulomatosis (author's transl)]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1981, Volume: 134, Issue:5 Topics: Azathioprine; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Liver; Lung; Middle	1981
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clinical nephrology, 1984, Volume: 21, Issue:6 Topics: Adolescent; Adult; Aged; Azathioprine; Blood Sedimentation; C-Reactive Protein; Cyclophosphamide; Dr	1984
Severe intestinal involvement in Wegener's granulomatosis. Gut, 1984, Volume: 25, Issue:11 Topics: Adult; Azathioprine; Cyclophosphamide; Diarrhea; Drug Therapy, Combination; Female; Granulomatosis w	1984
Wegener's granulomatosis with destructive ocular manifestations. American journal of ophthalmology, 1984, Dec-15, Volume: 98, Issue:6 Topics: Adult; Azathioprine; Cyclophosphamide; Eye; Eye Movements; Granuloma; Granulomatosis with Polyangiit	1984
Wegener's granulomatosis: observations on 18 patients with severe renal disease. The Quarterly journal of medicine, 1983,Autumn, Volume: 52, Issue:208 Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Po	1983
Necrotizing vasculitis (angiitis) with granulomatosis. International journal of dermatology, 1984, Volume: 23, Issue:2 Topics: Azathioprine; Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Granuloma, Lethal Midline; Gr	1984
Wegener's granulomatosis. Clinical features and outcome in 13 patients. Archives of internal medicine, 1983, Volume: 143, Issue:3 Topics: Adolescent; Aged; Antibiotics, Antineoplastic; Azathioprine; Cyclophosphamide; Female; Granulomatosi	1983
[Wegener's granulomatosis as a rare cause for kidney failure]. Acta medica Austriaca, 1983, Volume: 10, Issue:1 Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Adult; Azathioprine; Cyclophosphamide; Granulomatosis	1983
Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide. The American journal of medicine, 1980, Volume: 68, Issue:3 Topics: Adult; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppression T	1980
[Wegener's granulomatosis. Diagnosis and treatment]. Ugeskrift for laeger, 1982, Aug-16, Volume: 144, Issue:33 Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; M	1982
[Plasma exchange in rapidly progressive glomerulonephritis (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1981, Nov-27, Volume: 106, Issue:48 Topics: Adolescent; Adult; Aged; Anti-Glomerular Basement Membrane Disease; Antigen-Antibody Complex; Azathi	1981
Circulating immune complexes and the treatment of Wegener's granulomatosis. Nephron, 1981, Volume: 29, Issue:1-2 Topics: Adult; Antigen-Antibody Complex; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; H	1981
[Wegener's granulomatosis: characteristics of the clinical course and current treatment]. Terapevticheskii arkhiv, 1980, Volume: 52, Issue:4 Topics: Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Granulomatosis with Polyangiitis	1980
[The importance of early diagnosis of Wegener's granulomatosis: a typical problem case for the otolaryngologist (author's transl)]. HNO, 1980, Volume: 28, Issue:12 Topics: Adult; Autoimmune Diseases; Azathioprine; Female; Fluocortolone; Granulomatosis with Polyangiitis; H	1980
Necrotizing vasculitis--relapse despite cytotoxic therapy. Advances in experimental medicine and biology, 1993, Volume: 336 Topics: Adult; Aged; Arteritis; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Hu	1993
Relapses in patients with a systemic vasculitis. The Quarterly journal of medicine, 1993, Volume: 86, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Azathioprine	1993
Familial vasculitis: report of 2 families. The Journal of rheumatology, 1994, Volume: 21, Issue:3 Topics: Adult; Azathioprine; Child; Cyclophosphamide; Fatal Outcome; Female; Granulomatosis with Polyangiiti	1994
Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis. The American journal of the medical sciences, 1994, Volume: 308, Issue:2 Topics: Azathioprine; Eye Diseases; Female; Granulomatosis with Polyangiitis; Humans; Kidney; Middle Aged; P	1994
Treatment of Wegener's granulomatosis. Advances in experimental medicine and biology, 1993, Volume: 336 Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Granulom	1993
[Therapy of Wegener's granulomatosis. Experiences with conventional and stage-adjusted treatment in 111 patients over 24 years]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1993, Volume: 48, Issue:4 Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Drug Therap	1993
The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology, 1997, Volume: 104, Issue:4 Topics: Adolescent; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; Child; Cyclop	1997
Wegener's granulomatosis: controversies and current concepts. Comprehensive therapy, 1998, Volume: 24, Issue:9 Topics: Adolescent; Adult; Anti-Infective Agents; Azathioprine; Cyclophosphamide; Female; Folic Acid Antagon	1998
Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatric nephrology (Berlin, Germany), 2000, Volume: 14, Issue:3 Topics: Adolescent; Adult; Antigen-Antibody Reactions; Azathioprine; Child; Cyclophosphamide; Disease Progre	2000
Influenza A-associated bronchiolitis obliterans organizing pneumonia mimicking Wegener's granulomatosis. Rheumatology international, 2001, Volume: 20, Issue:3 Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cryptogenic Organizing Pneumonia; Diagnosis, D	2001
Azathioprine toxicity mimicking a relapse of Wegener's granulomatosis. Rheumatology (Oxford, England), 2001, Volume: 40, Issue:7 Topics: Azathioprine; Diagnosis, Differential; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged;	2001
Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clinic proceedings, 1977, Volume: 52, Issue:8 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arteritis; Asthma; Azathioprine; Cyclophosphamide;	1977
[Hyperergic collagenoses. Clinical aspects, differential diagnosis and therapy (author's transl)]. MMW, Munchener medizinische Wochenschrift, 1977, Oct-21, Volume: 119, Issue:42 Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; Derm	1977
Haemodialysis and transplantation in Wegener's granulomatosis. British medical journal, 1979, Jul-14, Volume: 2, Issue:6182 Topics: Adult; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Kidney Failure, Chr	1979
Some aspects of therapy in the non-healing granulomas of Wegener and Stewart. The Journal of otolaryngology, 1979, Volume: 8, Issue:1 Topics: Adult; Aged; Azathioprine; Female; Granuloma, Lethal Midline; Granulomatosis with Polyangiitis; Huma	1979
A rapid unfavorable outcome of Wegener's granulomatosis in early childhood. European journal of pediatrics, 1979, Volume: 131, Issue:4 Topics: Adrenal Cortex Hormones; Age Factors; Azathioprine; Child, Preschool; Cyclophosphamide; Female; Gran	1979
Wegener's granulomatosis: experience with 4 cases. The Journal of the Association of Physicians of India, 1979, Volume: 27, Issue:12 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Male	1979
Wegener's granulomatosis in childhood. A clinical report based on 3 cases. International journal of pediatric otorhinolaryngology, 1979, Volume: 1, Issue:2 Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Drug Therapy, Combination; Female; Granulo	1979
Wegener's granulomatosis. A clinicopathological study in twelve patients. The Netherlands journal of medicine, 1978, Volume: 21, Issue:5 Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Humans; Male;	1978
Successful renal transplantation in Wegener's granulomatosis. The American journal of medicine, 1976, Volume: 60, Issue:3 Topics: Adult; Azathioprine; Follow-Up Studies; Granulomatosis with Polyangiitis; Humans; Kidney Failure, Ch	1976
[Studies on the etiology of Wegener's granulomatosis. Apropos of a case with long survival]. Revista clinica espanola, 1977, Mar-31, Volume: 144, Issue:6 Topics: Adult; Azathioprine; Granulomatosis with Polyangiitis; Humans; Male; Prednisolone; Prognosis	1977
[Cholestatic jaundice after azathioprine treatment (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1976, Aug-13, Volume: 101, Issue:33 Topics: Adult; Azathioprine; Cholestasis; Female; Granulomatosis with Polyangiitis; Hepatitis; Humans; Male;	1976
[Azathioprine-induced icterus]. Die Medizinische Welt, 1976, Jul-02, Volume: 27, Issue:27 Topics: Adult; Azathioprine; Cholestasis; Female; Granulomatosis with Polyangiitis; Hepatitis; Humans; Male	1976
[Contribution to the clinical picture of Wegener's granulomatosis]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1976, Oct-15, Volume: 31, Issue:20 Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Diagnosis, Differential; Female; Granulomatosis with Po	1976
Treatment of Wegener's granulomatosis of lung. The American journal of medicine, 1975, Volume: 58, Issue:5 Topics: Azathioprine; Cyclophosphamide; Drug Evaluation; Granuloma; Granulomatosis with Polyangiitis; Hodgki	1975
Wegener's granulomatosis-controlled by azathioprine and corticosteroids. The British journal of dermatology, 1975, Volume: 92, Issue:4 Topics: Azathioprine; Biopsy; Granulomatosis with Polyangiitis; Humans; Kidney; Middle Aged; Prednisolone	1975
Differential diagnosis of midline facial granulomas. Southern medical journal, 1975, Volume: 68, Issue:10 Topics: Adult; Azathioprine; Cyclophosphamide; Diagnosis, Differential; Female; Granuloma, Lethal Midline; G	1975
Limited form of Wegener granulomatosis. Eye involvement as a major sign. JAMA, 1975, Aug-25, Volume: 233, Issue:8 Topics: Azathioprine; Biopsy; Blindness; Fundus Oculi; Granulomatosis with Polyangiitis; Humans; Lung; Male;	1975
Wegener's granulomatosis. Combined therapy with low-dosage systemic corticosteroids, azathioprine and cyclophosphamide in three patients. The British journal of dermatology, 1976, Volume: 94, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; G	1976
Crescentic glomerulonephritis in children. Pediatric nephrology (Berlin, Germany), 1992, Volume: 6, Issue:3 Topics: Adolescent; Adrenal Cortex Hormones; Anticoagulants; Azathioprine; Child; Child, Preschool; Cyclopho	1992
[Clinical experiences with Wegener's granulomatosis from the nephrologic viewpoint]. Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:17 Topics: Adolescent; Adult; Autoantibodies; Autoimmune Diseases; Azathioprine; Cyclophosphamide; Cytoplasm; D	1991
Treatment of primary systemic vasculitis. APMIS. Supplementum, 1990, Volume: 19 Topics: Adult; Arteritis; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Female; Granulomatos	1990
Prostatic involvement in Wegener's granulomatosis. The Journal of urology, 1987, Volume: 138, Issue:5 Topics: Aged; Azathioprine; Combined Modality Therapy; Cyclophosphamide; Granulomatosis with Polyangiitis; H	1987
Three cases of Wegener's granulomatosis treated with an antimicrobial agent. Archives of otolaryngology--head & neck surgery, 1989, Volume: 115, Issue:4 Topics: Adult; Anti-Infective Agents; Azathioprine; Drug Combinations; Drug Therapy, Combination; Female; Gr	1989
Cytomegalovirus retinitis in rheumatic disease: a case report. Arthritis and rheumatism, 1987, Volume: 30, Issue:1 Topics: Adult; Azathioprine; Cyclophosphamide; Cytomegalovirus Infections; Granulomatosis with Polyangiitis;	1987
Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis. American journal of nephrology, 1985, Volume: 5, Issue:1 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Azathioprine; Biopsy; Cyclophosphamide; Drug Therap	1985
[Reversible acute kidney failure in Wegener's granulomatosis]. Der Internist, 1985, Volume: 26, Issue:6 Topics: Acute Kidney Injury; Azathioprine; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combin	1985
[Treatment of Wegener's granulomatosis]. Deutsche medizinische Wochenschrift (1946), 1986, Jan-24, Volume: 111, Issue:4 Topics: Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Prednisone	1986
Wegener's granulomatosis arising in pregnancy. The Journal of laryngology and otology, 1986, Volume: 100, Issue:4 Topics: Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Prednisone; Pregnancy; Pregna	1986
Wegener granulomatosis in pediatric patients. The Journal of pediatrics, 1985, Volume: 106, Issue:5 Topics: Adolescent; Azathioprine; Child; Cyclophosphamide; Diagnosis, Differential; Female; Granulomatosis w	1985
Hodgkin's lymphoma in a patient treated for Wegener's granulomatosis with cyclophosphamide and azathioprine. The Journal of rheumatology, 1985, Volume: 12, Issue:3 Topics: Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Hodgkin Disease; Humans; Male; Mid	1985
Treatment of Wegener's granulomatosis. Lancet (London, England), 1973, Feb-10, Volume: 1, Issue:7798 Topics: Adult; Azathioprine; Granulomatosis with Polyangiitis; Humans; Male; Prednisone	1973
Immunological features of Wegener's granulomatosis. Lancet (London, England), 1974, Feb-23, Volume: 1, Issue:7852 Topics: Adult; Aged; Autoantibodies; Autoimmune Diseases; Azathioprine; Blood Proteins; Cell Migration Inhib	1974
[Successes and failures of immunosuppressive therapy in nephropathies]. Medizinische Klinik, 1974, Nov-08, Volume: 69, Issue:45 Topics: Adult; Anti-Glomerular Basement Membrane Disease; Azathioprine; Chronic Disease; Cortisone; Cyclopho	1974
Methotrexate therapy of Wegener's granulomatosis. Annals of internal medicine, 1971, Volume: 74, Issue:1 Topics: Adrenocorticotropic Hormone; Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans;	1971
Malignant granuloma. The British journal of oral surgery, 1972, Volume: 9, Issue:3 Topics: Adrenocorticotropic Hormone; Adult; Alveolar Process; Arteritis; Autopsy; Azathioprine; Biopsy; Gran	1972
Vasculitis presenting as otitis media. Southern medical journal, 1969, Volume: 62, Issue:2 Topics: Adult; Antimetabolites; Azathioprine; Blood Proteins; Diagnosis, Differential; Facial Paralysis; Fem	1969
Wegener's granulomatosis. Annals of internal medicine, 1974, Volume: 81, Issue:4 Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Diagnosis, Differe	1974
[Treatment of Wegener's granuloma with immunosuppressive and steroid drugs (author's transl)]. Laryngologie, Rhinologie, Otologie, 1974, Volume: 53, Issue:9 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cephalothin; Granulomatosis with Polyangiitis; Humans;	1974
Non-healing granulomata of the upper respiratory tract. British medical journal, 1974, Oct-26, Volume: 4, Issue:5938 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Blood Sedimentation; Child; Female;	1974
[Indications for immunosuppressive agents in glomerular nephropathies]. Annales de medecine interne, 1974, Volume: 125, Issue:11 Topics: Adrenal Cortex Hormones; Anti-Glomerular Basement Membrane Disease; Azathioprine; Chlorambucil; Cycl	1974
[3-year observation of Wegener's graunlomatosis]. Zeitschrift fur Erkrankungen der Atmungsorgane, 1974, Volume: 140, Issue:1 Topics: Adult; Azathioprine; Bone Marrow Examination; Diagnosis, Differential; Follow-Up Studies; Granulomat	1974
Wegener's granulomatosis. The New Zealand medical journal, 1974, May-22, Volume: 79, Issue:516 Topics: Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Lung; Middle Aged; Prednisone	1974
Renal transplantation in a patient with Wegener's granulomatosis. American journal of surgery, 1972, Volume: 124, Issue:1 Topics: Acute Kidney Injury; Adult; Animals; Azathioprine; Biopsy; Globulins; Granulomatosis with Polyangiit	1972
Renal biopsy pathology in Wegener's granulomatosis. The American journal of pathology, 1974, Volume: 74, Issue:3 Topics: Antigen-Antibody Complex; Azathioprine; Biopsy; Blood Urea Nitrogen; Cyclophosphamide; Granulomatosi	1974
Acute fulminant Wegener granulomatosis. Therapy with immunosuppression, hemodialysis, and renal transplantation. Archives of internal medicine, 1974, Volume: 134, Issue:1 Topics: Acute Disease; Adult; Antilymphocyte Serum; Azathioprine; Fluorescent Antibody Technique; Granulomat	1974
Wegener's granulomatosis. Treatment with heparin in addition to azathioprine and corticosteroids. Nephron, 1972, Volume: 9, Issue:4 Topics: Acute Kidney Injury; Azathioprine; Biopsy; Granulomatosis with Polyangiitis; Heparin; Humans; Kidney	1972
[Clinical aspects of Wegener's granulomatosis]. Munchener medizinische Wochenschrift (1950), 1972, Sep-29, Volume: 114, Issue:39 Topics: Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Mercaptopurine; Middle Aged; Oral Ma	1972
Reversal of renal failure in Wegener's granulomatosis cy heparin. The American journal of the medical sciences, 1973, Volume: 265, Issue:5 Topics: Azathioprine; Biopsy; Blood Coagulation Tests; Disseminated Intravascular Coagulation; Female; Fibri	1973
[Wegener's granulomatosis in otological form. (Diagnosis and evolution during immunodepressive treatment)]. Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1973, Volume: 90, Issue:3 Topics: Azathioprine; Betamethasone; Cortisone; Cyclophosphamide; Deafness; Ear Diseases; Eye Manifestations	1973
Reversal of rapidly progressive renal failure associated with polyarteritis. Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:7 Topics: Arteritis; Azathioprine; Glomerulonephritis; Granulomatosis with Polyangiitis; Humans; Male; Middle	1973
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine, 1973, Volume: 52, Issue:6 Topics: Adult; Aged; Azathioprine; Biopsy; Corneal Ulcer; Cyclophosphamide; Diagnosis, Differential; Ear Dis	1973
[Papulosis atrophicans maligna (Köhlmeier-Degos) and Wegener's granulomatosis in a sister and brother (author's transl)]. Medizinische Klinik, 1974, May-24, Volume: 69, Issue:21 Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Cyclophosphamide; Diet Therapy; Female; Glutens; Granul	1974
Wegener's granulomatosis in a child. Observations on pathogenesis and treatment. American journal of diseases of children (1960), 1969, Volume: 118, Issue:4 Topics: Adolescent; Azathioprine; Epistaxis; Fluorescent Antibody Technique; Granulomatosis with Polyangiiti	1969
[Immunosuppressive therapy of Wegener's granulomatosis]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1971, Oct-15, Volume: 26, Issue:20 Topics: Azathioprine; Biopsy; Chlorambucil; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppress	1971
[Immunosuppressive therapy in Wegener's granulomatosis]. Das Deutsche Gesundheitswesen, 1972, Jul-06, Volume: 27, Issue:27 Topics: Azathioprine; Drug Combinations; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Isonicot	1972
[Course of Wegener's granulomatosis during corticosteroid-imurek therapy]. Die Medizinische Welt, 1972, Aug-26, Volume: 23, Issue:35 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Drug Synergism; Granulomatosis with Polyangiitis; Huma	1972
Wegener's granuloma treated with azathioprine. Proceedings of the Royal Society of Medicine, 1972, Volume: 65, Issue:7 Topics: Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Middle Aged; Otitis Media	1972
The treatment of Wegener's granulomatosis with immunosuppressive-cytotoxic drugs. The Journal of laryngology and otology, 1971, Volume: 85, Issue:7 Topics: Adult; Azathioprine; Chlorambucil; Female; Granulomatosis with Polyangiitis; Humans; Male; Methylpre	1971
[Wegener's granulomatosis. Diagnostic problems and clinical course under immunosuppressive therapy]. Schweizerische medizinische Wochenschrift, 1971, Aug-07, Volume: 101, Issue:31 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chlorambucil; Female; Granulomatosis with Polyangiitis	1971
Microangiopathic hemolytic anemia in Wegener's granulomatosis. The American journal of medicine, 1971, Volume: 51, Issue:4 Topics: Allopurinol; Anemia, Hemolytic; Azathioprine; Granulomatosis with Polyangiitis; Heparin; Humans; Mal	1971
[Radiographic study of healing in Wegener's granulomatosis]. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1971, Volume: 115, Issue:4 Topics: Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Lung Diseases; Male; Middle A	1971
Remission in Wegener's granulomatosis treated with steroids and azathioprine. New York state journal of medicine, 1969, May-01, Volume: 69, Issue:9 Topics: Adult; Azathioprine; Female; Granulomatosis with Polyangiitis; Humans; Prednisone	1969
Sustained azathioprine-induced remission in Wegener's granulomatosis. British medical journal, 1969, Dec-06, Volume: 4, Issue:5683 Topics: Azathioprine; Central Nervous System Diseases; Drug Synergism; Female; Granulomatosis with Polyangii	1969
[Immunosuppressive therapy of Wegener's granulomatosis]. Orvosi hetilap, 1969, Sep-14, Volume: 110, Issue:37 Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Granulomatosis with Polyangiitis; Humans; Immunosuppre	1969
Treatment of Wegener's granulomatosis with immunosuppressive agents. Description of renal ultrastructure. Archives of internal medicine, 1970, Volume: 126, Issue:2 Topics: Adult; Aged; Alkylating Agents; Azathioprine; Biopsy; Female; Granulomatosis with Polyangiitis; Huma	1970
A case of Wegener's disease. Practica oto-rhino-laryngologica, 1970, Volume: 32, Issue:3 Topics: Adult; Anticoagulants; Azathioprine; Granulomatosis with Polyangiitis; Humans; Kidney Function Tests	1970
Wegener's granuloma complicating pregnancy. The Journal of obstetrics and gynaecology of the British Commonwealth, 1970, Volume: 77, Issue:11 Topics: Adult; Azathioprine; Female; Folic Acid; Fumarates; Granulomatosis with Polyangiitis; Humans; Predni	1970
[Immunosuppressive effect of cytostatics in the clinic]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1970, Jul-21, Volume: 59, Issue:29 Topics: Azathioprine; Colitis, Ulcerative; Collagen Diseases; Granulomatosis with Polyangiitis; Hematologic	1970
Wegener's granulomatosis: treatment with cytotoxic agents and adrenocorticoids. Annals of internal medicine, 1971, Volume: 74, Issue:3 Topics: Adult; Antineoplastic Agents; Azathioprine; Biopsy; Chlorambucil; Creatinine; Cyclophosphamide; Fema	1971
Wegener's granulomatosis of lung: diagnosis and treatment. Experience with 12 cases. Annals of internal medicine, 1971, Volume: 74, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Azathioprine; Chlorambucil; Female; Granulomatosis with Polyangi	1971
[Exogenous and endogenous (hyperparathyroidism, Wegener's granulomatosis) poisonings]. Helvetica medica acta, 1967, Volume: 34, Issue:1 Topics: Adenoma; Adult; Aged; Arsenic Poisoning; Autoimmune Diseases; Azathioprine; Child, Preschool; Diagno	1967
Treatment of advanced Wegener's granulomatosis with azathioprine and duazomycin A. The New England journal of medicine, 1968, Feb-01, Volume: 278, Issue:5 Topics: Adult; Antibody Formation; Antimetabolites; Azathioprine; Azo Compounds; Diazooxonorleucine; Granulo	1968
Antimetabolites and immunoinflammatory diseases. The New England journal of medicine, 1968, Feb-01, Volume: 278, Issue:5 Topics: Antimetabolites; Azathioprine; Granulomatosis with Polyangiitis; Humans	1968
Combined corticosteroid and azathioprine therapy in 2 patients with Wegener's granulomatosis. Archives of internal medicine, 1968, Volume: 121, Issue:6 Topics: Adult; Azathioprine; Biopsy; Blood Urea Nitrogen; Female; Granulomatosis with Polyangiitis; Humans;	1968
[Ocular involvement in Wegener's granulomatosis]. Klinische Monatsblatter fur Augenheilkunde, 1968, Volume: 153, Issue:5 Topics: Aged; Azathioprine; Diagnosis, Differential; Eye Manifestations; Female; Granulomatosis with Polyang	1968
[3 cases of intravitally diagnosed Wegener's granulomatosis. Diagnosis, course and therapy]. Deutsche medizinische Wochenschrift (1946), 1969, May-02, Volume: 94, Issue:18 Topics: Adrenal Cortex Hormones; Azathioprine; Biopsy; Blood Sedimentation; Coombs Test; Female; Granulomato	1969

azathioprine and Granulomatosis, Wegener's

Research Excerpts

Research

Studies (230)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Disease Remission

Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization

Number of Subjects Experiencing Serious Adverse Events

Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy

The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups

The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups

Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups

Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups

Disease Improvement

Disease Relapse

Disease Remission

Meeting Common Closing

Safety of Abatacept - Number of Participants With Adverse Events

ACR20 at Month 3 in Adults

C-Reactive Protein

Childhood Health Assessment Questionnaire

Death

Dosing Period

Health Assessment Questionnaire Disability Index

JRA DOI 30 at Month 3 in Juveniles

Lymphoma

Malignancy

Serious Infectious Event

Standardized Incidence Rate for All SEER Cancers

Swollen Joint Count

Tender Joint Count

Total Exposure Adjusted Rate of Deaths

Total Exposure Adjusted Rate of Lymphomas

Total Exposure Adjusted Rate of Malignancies

Total Exposure Adjusted Rate of Serious Adverse Events

Total Exposure Adjusted Rate of Serious Infectious Events

Total Exposure to Etanercept With Gaps

Reviews

Trials

Other Studies